Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

CordenPharma boosts lipids in Colorado

by Rick Mullin
April 24, 2021 | A version of this story appeared in Volume 99, Issue 15

 

A photo of CordenPharma's facility in Colorado.
Credit: CordenPharma
CordenPharma purifies lipids at this facility in Colorado.

CordenPharma is adding lipid purification capacity at its facility in Boulder, Colorado, in response to mounting demand for lipid nanoparticles needed to make messenger RNA–based COVID-19 vaccines. The German drug services firm manufactures cationic lipids, pegylated lipids, distearoylphosphatidylcholine phospholipids, and plant-based cholesterol stabilizers—all used in vaccines. The firm expects the expansion to accelerate lipids delivery by July. The expansion is the latest in a series of investments by CordenPharma, which supplies lipid excipients to Moderna.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.